About
SoniVie Ltd is a medical device company focused on developing innovative ultrasound-based therapeutic technologies for treating hypertension and related cardiovascular and pulmonary conditions. Founded in 2014 and headquartered in Israel, with operations in the US and Europe, SoniVie specializes in its proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS™) system. This system targets nerves surrounding blood vessels to perform renal denervation and other therapies aimed at reducing blood pressure. The TIVUS™ system is the only ultrasound denervation platform actively being developed for three therapeutic areas: pulmonary artery denervation for pulmonary hypertension, renal artery denervation for resistant hypertension, and lung denervation for chronic obstructive pulmonary disease (COPD). The technology is currently investigational and undergoing clinical trials, including a pivotal trial with the FDA. SoniVie has received multiple FDA Breakthrough Device Designations, reflecting its innovative approach. The company recently completed a $60 million Series C financing round to support its clinical and regulatory efforts. In 2025, SoniVie is set to be acquired by Boston Scientific Corporation, enhancing its presence in the cardiovascular device market.
Technologies
Keywords
Company Information
- Employees20
- Founded2014
- Total Funding$60000000
Location
22 שבזי, Rosh Haayin, Center District, Israel, 4802122
